|
Ibrutinib vs chlorambucil: Immunophenotypic and quantitative impacts on circulating immune cells in chronic lymphocytic leukemia (CLL). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Consulting or Advisory Role - Abbvie; Genentech; Gilead Sciences |
Research Funding - Abbvie; Genentech; Pharmacyclics |
|
|
Consulting or Advisory Role - Janssen; Portola Pharmaceuticals |
Research Funding - Gilead Sciences; Pharmacyclics |
Travel, Accommodations, Expenses - Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
Patents, Royalties, Other Intellectual Property - Pharmacyclics |
|
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
|
|
Employment - Amgen; Pharmacyclics |
Stock and Other Ownership Interests - Abbvie; Amgen |
Patents, Royalties, Other Intellectual Property - Amgen; Miravant Medical |